Just caught that Braidwell trimmed their Xenon stake pretty hard in Q4 - sold off nearly 1.8M shares for about $75 million. Position went from meaningful to just 2.6% of their fund, which is honestly telling.

The timing is interesting because Xenon's Phase 3 data for azetukalner was supposed to drop in March (we're past that now), so either they're getting ahead of potential downside or just rebalancing risk. Stock's been pretty flat - only up like 6% over the past year, which is weak for biotech.

What gets me is they're not bailing entirely, just right-sizing. Xenon's still sitting on a bunch of late-stage programs across epilepsy and neuropsych, so there's still optionality there. But yeah, when big holders start trimming positions like this, it usually means they're not betting the farm on any single outcome. Smart move honestly - biotech is binary and diversification matters.